AGE restriction in diabetes mellitus: A paradigm shift

Nature Reviews Endocrinology

Volumn 7, Issue 9, 2011, Pages 526-539

  Vlassara, Helen ^a   Striker, Gary E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; 6 N CARBOXYMETHYLLYSINE; 8 ISOPROSTANE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; APOLIPOPROTEIN B; CD36 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; MANGANESE SUPEROXIDE DISMUTASE; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYELOID DIFFERENTIATION FACTOR 88; NICOTINATE PHOSPHORIBOSYLTRANSFERASE; PROTEIN KINASE C; PROTEIN P66; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SCAVENGER RECEPTOR B; SIRTUIN 1; SYNAPTOTAGMIN I; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASCULOTROPIN;

DIABETES MELLITUS; DIET RESTRICTION; EPIGENETICS; HOST RESISTANCE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIENT; OBESITY; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN RESISTANCE; OXIDATIVE STRESS;

EID: 80052059557     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.74     Document Type: Review

References (177)

1. Amos, A. F., McCarty, D. J. & Zimmet, P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet. Med. 14 (Suppl. 5), S1-S85 (1997).
2. Dandona, P., Aljada, A., Chaudhuri, A., Mohanty, P. & Garg, R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111, 1448-1454 (2005). (Pubitemid 40396812)
3. Ford, E. S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care, 28, 1769-1778 (2005). (Pubitemid 40923091)
4. Fox, C. S. et al. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation 113, 2914-2918 (2006). (Pubitemid 44297232)
5. Harjutsalo, V., Sjöberg, L. & Tuomilehto, J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 371, 1777-1782 (2008). (Pubitemid 351697953)
6. Grundy, S. M. Metabolic syndrome pandemic. Arterioscler. Thromb. Vasc. Biol. 28, 629-636 (2008). (Pubitemid 351651324)
7. Bashan, N., Kovsan, J., Kachko, I., Ovadia, H. & Rudich, A. Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol. Rev. 89, 27-71 (2009).
8. Wong, T. Y. et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet 371, 736-743 (2008). (Pubitemid 351288874)
9. ACCORD Study Group. et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575-1585 (2010).
10. [No authors listed] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N. Engl. J. Med., 342, 381-389 (2000).
11. Skyler, J. S. et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J. Am. Coll. Cardiol. 53, 298-304 (2009).
12. Parthasarathy, S., Khan-Merchant, N., Penumetcha, M., Khan, B. V. & Santanam, N. Did the antioxidant trials fail to validate the oxidation hypothesis? Curr. Atheroscler. Rep. 3, 392-398 (2001).
13. Ruderman, N., Chisholm, D., Pi-Sunyer, X. & Schneider, S. The metabolically obese, normal-weight individual revisited. Diabetes 47, 699-713 (1998). (Pubitemid 28201798)
14. Wildman, R. P. et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch. Intern. Med. 168, 1617-1624 (2008).
15. Knip, M. et al. Environmental triggers and determinants of type 1 diabetes. Diabetes 54 (Suppl. 2), S125-S136 (2005). (Pubitemid 43348458)
16. Huebschmann, A. G., Regensteiner, J. G., Vlassara, H. & Reusch, J. E. Diabetes and advanced glycoxidation end products. Diabetes Care 29, 1420-1432 (2006). (Pubitemid 44125953)
17. Vlassara, H. & Striker, G. Glycotoxins in the diet promote diabetes and diabetic complications. Curr. Diab. Rep. 7, 235-241 (2007). (Pubitemid 46951921)
18. Wentworth, J. M., Fourlanos, S. & Harrison, L. C. Reappraising the stereotypes of diabetes in the modern diabetogenic environment. Nat. Rev. Endocrinol. 5, 483-489 (2009).
19. Koschinsky, T. et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc. Natl Acad. Sci. USA 94, 6474-6479 (1997). (Pubitemid 27270709)
20. Uribarri, J. et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J. Gerontol. A Biol. Sci. Med. Sci. 62, 427-433 (2007). (Pubitemid 47065712)
21. Vlassara, H. et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J. Clin. Endocrinol. Metab. 94, 4483-4491 (2009).
22. Brands, C. M., Alink, G. M., van Boekel, M. A. & Jongen, W. M. Mutagenicity of heated sugar-casein systems: effect of the Maillard reaction. J. Agric. Food Chem. 48, 2271-2275 (2000). (Pubitemid 30431225)
23. Cai, W. et al. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol. Med. 8, 337-346 (2002). (Pubitemid 35346213)
24. Finot, P. A. Historical perspective of the Maillard reaction in food science. Ann. NY Acad. Sci. 1043, 1-8 (2005).
25. Finot, P. A. The absorption and metabolism of modified amino acids in processed foods. J. AOAC Int. 88, 894-903 (2005).
26. Ames, J. M. Determination of N epsilon-(carboxymethyl)lysine in foods and related systems. Ann. NY Acad. Sci. 1126, 20-24 (2008). (Pubitemid 351589292)
27. Pouillart, P. et al. Strategy for the study of the health impact of dietary Maillard products in clinical studies: the example of the ICARE clinical study on healthy adults. Ann. NY Acad. Sci. 1126, 173-176 (2008). (Pubitemid 351589302)
28. Birlouez-Aragon, I. et al. A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am. J. Clin. Nutr. 91, 1220-1226 (2010).
29. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820 (2001). (Pubitemid 34000785)
30. Vlassara, H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab. Res. Rev. 17, 436-443 (2001). (Pubitemid 34030746)
31. Zhao, Z. et al. Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis. Endocrinology 150, 2569-2576 (2009).
32. Fu, M. X. et al. The advanced glycation end product, Nepsilon- (carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 271, 9982-9986 (1996).
33. Schalkwijk, C. G., Stehouwer, C. D. & van Hinsbergh, V. W. Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification. Diabetes Metab. Res. Rev. 20, 369-382 (2004). (Pubitemid 39302962)
34. Zhang, Q., Ames, J. M., Smith, R. D., Baynes, J. W. & Metz, T. O. A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease. J. Proteome Res. 8, 754-769 (2009).
35. Baynes, J. W. & Thorpe, S. R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48, 1-9 (1999). (Pubitemid 29019345)
36. Monnier, V. M. et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 48, 870-880 (1999). (Pubitemid 29153089)
37. Bucala, R., Makita, Z., Koschinsky, T., Cerami, A. & Vlassara, H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc. Natl Acad. Sci. USA 90, 6434-6438 (1993). (Pubitemid 23207227)
38. Thornalley, P. J. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-a role in pathogenesis and antiproliferative chemotherapy. Gen. Pharmacol. 27, 565-573 (1996). (Pubitemid 26233322)
39. Rabbani, N. & Thornalley, P. J. The dicarbonyl proteome: proteins susceptible to dicarbonyl glycation at functional sites in health, aging, and disease. Ann. NY Acad. Sci. 1126, 124-127 (2008). (Pubitemid 351589305)
40. Maillard, L. C. Action des acides anines sur les sucres: formation des melanoidines par voie methodique. Crit. Rev. Acad. Sci. 154, 1653-1671 (1912).
41. Uribarri, J. et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J. Am. Diet Assoc. 110, 911-916 (2009).
42. Goldberg, T. et al. Advanced glycoxidation end products in commonly consumed foods. J. Am. Diet Assoc. 104, 1287-1291 (2004). (Pubitemid 39036519)
43. OBrien, J. & Morrissey, P. A. Nutritional and toxicological aspects of the Maillard browning reaction in foods. Crit. Rev. Food Sci. Nutr. 28, 211-248 (1989).
44. Makita, Z., Vlassara, H., Cerami, A. & Bucala, R. Immunochemical detection of advanced glycosylation end products in vivo. J. Biol. Chem. 267, 5133-5138 (1992).
45. Mitsuhashi, T., Vlassara, H., Founds, H. W. & Li, Y. M. Standardizing the immunological measurement of advanced glycation endproducts using normal human serum. J. Immunol. Methods 207, 79-88 (1997). (Pubitemid 27400475)
46. Semba, R. D., Nicklett, E. J. & Ferrucci, L. Does accumulation of advanced glycation end products contribute to the aging phenotype? J. Gerontol. A Biol. Sci. Med. Sci. 65, 963-975 (2010).
47. Kilhovd, B. K. et al. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 50, 1409-1417 (2007). (Pubitemid 46879016)
48. Samuel, V. T., Petersen, K. F. & Shulman, G. I. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375, 2267-2277 (2010).
49. Bucala, R. et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc. Natl Acad. Sci. USA 91, 9441-9445 (1994). (Pubitemid 24297930)
50. Januszewski, A. S., Alderson, N. L., Jenkins, A. J., Thorpe, S. R. & Baynes, J. W. Chemical modification of proteins during peroxidation of phospholipids. J. Lipid Res. 46, 1440-1449 (2005). (Pubitemid 43109808)
51. Stitt, A. W. et al. Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationships to tissue AGEs. Mol. Med. 3, 617-627 (1997). (Pubitemid 27465233)
52. Staprans, I., Rapp, J. H., Pan, X. M. & Feingold, K. R. Oxidized lipids in the diet are incorporated by the liver into very low density lipoprotein in rats. J. Lipid Res. 37, 420-430 (1996). (Pubitemid 26078958)
53. Staprans, I., Pan, X. M., Rapp, J. H. & Feingold, K. R. Oxidized cholesterol in the diet is a source of oxidized lipoproteins in human serum. J. Lipid Res. 44, 705-715 (2003). (Pubitemid 37279672)
54. Cai, W. et al. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 110, 285-291 (2004). (Pubitemid 38955497)
55. Hodgkinson, C. P., Laxton, R. C., Patel, K. & Ye, S. Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28, 2275-2281 (2008).
56. Nathan, C. Epidemic inflammation: pondering obesity. Mol. Med. 14, 485-492 (2008).
57. Itoh, Y. et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422, 173-176 (2003). (Pubitemid 36362750)
58. Shi, H. et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116, 3015-3025 (2006). (Pubitemid 44684486)
59. Adachi, T., Inoue, M., Hara, H., Maehata, E. & Suzuki, S. Relationship of plasma extracellular-superoxide dismutase level with insulin resistance in type 2 diabetic patients. J. Endocrinol. 181, 413-417 (2004). (Pubitemid 38868191)
60. Shinohara, M. et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J. Clin. Invest. 101, 1142-1147 (1998). (Pubitemid 28125293)
61. Anderson, M. M. & Heinecke, J. W. Production of Nη- (carboxymethyl)lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of advanced glycation end products during inflammation. Diabetes 52, 2137-2143 (2003). (Pubitemid 36919809)
62. Thornalley, P. J. Glyoxalase I-structure, function and a critical role in the enzymatic defence against glycation. Biochem. Soc. Trans. 31, 1343-1348 (2003). (Pubitemid 38030973)
63. Makita, Z. et al. Advanced glycosylation end products in patients with diabetic nephropathy. N. Engl. J. Med. 325, 836-842 (1991).
64. Makita, Z. et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343, 1519-1522 (1994). (Pubitemid 24180047)
65. Skolnik, E. Y. et al. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J. Exp. Med. 174, 931-939 (1991).
66. He, C. J. et al. Differential expression of renal AGE-receptor genes in NOD mouse kidneys: possible role in non-obese diabetic renal disease. Kidney Int. 58, 1931-1940 (2000).
67. Sindhu, R. K., Koo, J. R., Roberts, C. K. & Vaziri, N. D. Dysregulation of hepatic superoxide dismutase, catalase and glutathione peroxidase in diabetes: response to insulin and antioxidant therapies. Clin. Exp. Hypertens. 26, 43-53 (2004). (Pubitemid 38248221)
68. van Boekel, M. A. Formation of flavour compounds in the Maillard reaction. Biotechnol. Adv. 24, 230-233 (2006). (Pubitemid 43172054)
69. Zamora, R. & Hidalgo, F. J. Coordinate contribution of lipiod oxidation and maillard reaction to the nonenzymatic food browning. Crit. Rev. Food Sci. Nutr. 45, 49-59 (2005). (Pubitemid 41662116)
70. Tessier, F. J. & Niquet, C. The metabolic, nutritional and toxicological consequences of ingested dietary Maillard reaction products: a literature review [French]. J. Soc. Biol. 201, 199-207 (2007). (Pubitemid 350033591)
71. He, C., Sabol, J., Mitsuhashi, T. & Vlassara, H. Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 48, 1308-1315 (1999). (Pubitemid 29241031)
72. Cai, W. et al. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. Am. J. Pathol. 170, 1893-1902 (2007). (Pubitemid 47339263)
73. Cai, W. et al. Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am. J. Pathol. 173, 327-336 (2008).
74. Lin, R. Y. et al. Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis 163, 303-311 (2002).
75. Zheng, F. et al. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab. Res. Rev. 18, 224-237 (2002). (Pubitemid 34778386)
76. Lin, R. Y. et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 168, 213-220 (2003).
77. Schmidt, A. M. & Stern, D. M. Receptor for age (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease. Front. Biosci. 6, D1151-D1160 (2001).
78. Coughlan, M. T. et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J. Am. Soc. Nephrol. 20, 742-752 (2009).
79. Lu, C. et al. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc. Natl Acad. Sci. USA 101, 11767-11772 (2004). (Pubitemid 39099304)
80. Cai, W., He, J. C., Zhu, L., Lu, C. & Vlassara, H. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc. Natl Acad. Sci. USA 103, 13801-13806 (2006). (Pubitemid 44413988)
81. Torreggianni, M. et al. Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia. Am. J. Pathol. 175, 1722-1732 (2009).
82. Liang, F., Kume, S. & Koya, D. SIRT1 and insulin resistance. Nat. Rev. Endocrinol. 5, 367-373 (2009).
83. Yoshizaki, T. et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol. Cell Biol. 29, 1363-1374 (2009).
84. de Kreutzenberg, S. V. et al. Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. Diabetes 59, 1006-1015 (2010).
85. He, C. J., Koschinsky, T., Buenting, C. & Vlassara, H. Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE. Mol. Med. 7, 159-168 (2001). (Pubitemid 33701987)
86. Menghini, R. et al. MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation 120, 1524-1532 (2009).
87. Cai, W. et al. AGE-receptor-1 counteracts cellular oxidant stress induced by AGEs via negative regulation of p66shc-dependent FKHRL1 phosphorylation. Am. J. Physiol. Cell Physiol. 294, C145-C152 (2008).
88. Urribarri, J. et al. Improved insulin resistance in human type 2 diabetes by AGE-restriction; potential role of AGER1 and SIRT1. Diabetes doi:10.2337/DC11-0091.
89. Vlassara, H., Brownlee, M. & Cerami, A. Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J. Exp. Med. 164, 1301-1309 (1986). (Pubitemid 16031623)
90. Vlassara, H., Brownlee, M. & Cerami, A. High-affinity-receptor- mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc. Natl Acad. Sci. USA 82, 5588-5592 (1985). (Pubitemid 16218810)
91. Yamagata, T. et al. Genome organization of human 48-kDa oligosaccharyltransferase (DDOST). Genomics 45, 535-540 (1997). (Pubitemid 27506128)
92. Silberstein, S., Kelleher, D. J. & Gilmore, R. The 48-kDa subunit of the mammalian oligosaccharyltransferase complex is homologous to the essential yeast protein WBP1. J. Biol. Chem. 267, 23658-23663 (1992). (Pubitemid 23088169)
93. Goldin, A., Beckman, J. A., Schmidt, A. M. & Creager, M. A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114, 597-605 (2006). (Pubitemid 44199649)
94. Kislinger, T. et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 21, 905-910 (2001). (Pubitemid 34168644)
95. Ohgami, N. et al. CD36, a member of class B scavenger receptor family, is a receptor for advanced glycation end products. Ann. NY Acad. Sci. 947, 350-355 (2001). (Pubitemid 34059934)
96. Kislinger, T. et al. Nη-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274, 31740-31749 (1999).
97. Cai, W. et al. AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC-delta: implications for vascular disease. Am. J. Physiol. Cell Physiol. 298, C624-C634 (2009).
98. Wautier, M. P. et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 280, E685-E694 (2001).
99. Basbaum, C., Li, D., Gensch, E., Gallup, M. & Lemjabbar, H. Mechanisms by which gram-positive bacteria and tobacco smoke stimulate mucin induction through the epidermal growth factor receptor (EGFR). Novartis Found. Symp. 248, 171-6; discussion 176-180, 277-282 (2002).
100. Fukuhara, S., Chikumi, H. & Gutkind, J. S. RGS-containing RhoGEFs: the missing link between transforming G proteins and Rho? Oncogene 20, 1661-1668 (2001). (Pubitemid 32336855)
101. Napoli, C. et al. Deletion of the p66Shc longevity gene reduces systemic and tissue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed a high-fat diet. Proc. Natl Acad. Sci. USA 100, 2112-2116 (2003). (Pubitemid 36254582)
102. Migliaccio, E. et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 402, 309-313 (1999).
103. Li, Y. M., Tan, A. X. & Vlassara, H. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat. Med. 1, 1057-1061 (1995).
104. Gao, X., Zhang, H., Schmidt, A. M. & Zhang, C. AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am. J. Physiol. Heart Circ. Physiol. 295, H491-H498 (2008).
105. Deane, R. et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9, 907-913 (2003). (Pubitemid 36889934)
106. Bierhaus, A. et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-?B. Diabetes 50, 2792-2808 (2001). (Pubitemid 33733131)
107. Basta, G., Schmidt, A. M. & De Caterina, R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res. 63, 582-592 (2004). (Pubitemid 39078671)
108. Branco-Madeira, F. & Lambrecht, B. N. High mobility group box-1 recognition: the beginning of a RAGEless era? EMBO Mol. Med. 2, 193-195 (2010).
109. Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R. & Coyle, A. J. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 28, 367-388 (2010).
110. Qin, Y. H. et al. HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products. J. Immunol. 183, 6244-6250 (2009).
111. Yao, D. & Brownlee, M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 59, 249-255 (2010).
112. Wang, Y. et al. sRAGE induces human monocyte survival and differentiation. J. Immunol. 185, 1822-1835 (2010).
113. van Beijnum, J. R., Buurman, W. A. & Griffioen, A. W. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 11, 91-99 (2008).
114. Sourris, K. C. et al. Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor. Diabetologia 53, 2442-2451.
115. Tikellis, C. et al. Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs. Am. J. Physiol. Endocrinol. Metab. 295, E323-E330 (2008).
116. Vlassara, H., Brownlee, M. & Cerami, A. Specific macrophage receptor activity for advanced glycosylation end products inversely correlates with insulin levels in vivo. Diabetes 37, 456-461 (1988). (Pubitemid 18096384)
117. Mitsuhashi, T., Li, Y. M., Fishbane, S. & Vlassara, H. Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix. J. Clin. Invest. 100, 847-854 (1997). (Pubitemid 27371703)
118. Vlassara, H. et al. Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging. Kidney Int. Suppl. 114, S3-S11 (2009).
119. Vlassara, H. et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl Acad. Sci. USA 91, 11704-11708 (1994). (Pubitemid 24356413)
120. Oberg, B. P. et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 65, 1009-1016 (2004). (Pubitemid 38251077)
121. Wu, J. et al. Induction of diabetes in aged C57B6 mice results in severe nephropathy: an association with oxidative stress, endoplasmic reticulum stress, and inflammation. Am. J. Pathol. 176, 2163-2176 (2010).
122. Vlassara, H. et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc. Natl Acad. Sci. USA 99, 15596-15601 (2002). (Pubitemid 35403978)
123. Vlassara, H., Fuh, H., Makita, Z., Krungkrai, S., Cerami, A. & Bucala, R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc. Natl Acad. Sci. USA 89, 12043-12047 (1992). (Pubitemid 23004781)
124. Onorato, J. M., Jenkins, A. J., Thorpe, S. R. & Baynes, J. W. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J. Biol. Chem. 275, 21177-21184 (2000). (Pubitemid 30481811)
125. Metz, T. O., A. N., Chahich, M. E., Thorpe, S. R. & Baynes, J. W. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J. Biol. Chem. 278, 42012-42019 (2003). (Pubitemid 37310465)
126. Wolffenbuttel, B. H. et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc. Natl Acad. Sci. USA 95, 4630-4634 (1998).
127. Degenhardt, T. P. et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 61, 939-950 (2002). (Pubitemid 34175462)
128. Hofmann, S. M. et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 51, 2082-2089 (2002). (Pubitemid 34729011)
129. Peppa, M. et al. Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes 52, 1441-1448 (2003). (Pubitemid 36666199)
130. Sandu, O. et al. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 54, 2314-2319 (2005). (Pubitemid 41134257)
131. Odegaard, A. O. & Pereira, M. A. Trans fatty acids, insulin resistance, and type 2 diabetes. Nutr. Rev. 64, 364-372 (2006). (Pubitemid 44291089)
132. Brownlee, M., Cerami, A. & Vlassara, H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318, 1315-1321 (1988).
133. Stitt, A. W. et al. Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3. Diabetes 54, 785-794 (2005). (Pubitemid 40322083)
134. Olefsky, J. M. & Glass, C. K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72, 219-246 (2010).
135. Hotamisligil, G. S. & Spiegelman, B. M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 43, 1271-1278 (1994).
136. Scherer, P. E. Adipose tissue: from lipid storage to compartment to endocrine organ. Diabetes 55, 1537-1545 (2006). (Pubitemid 44324105)
137. Wang, P., Mariman, E., Renes, J. & Keijer, J. The secretory function of adipocytes in the phyriology of white adipose tissue. J. Cell Physiol. 216, 3-13 (2008). (Pubitemid 351813090)
138. Nguyen, M. T. et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J. Biol. Chem. 282, 357279-357292 (2008).
139. Patsouris, D. et al. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 8, 301-309 (2008).
140. Nishimura, S. et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 15, 914-920 (2009).
141. Feuerer, M. et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15, 930-939 (2009).
142. Winer, S. et al. Obesity predisposes to Th17 bias. Eur. J. Immunol. 39, 2629-2635 (2009).
143. Vlassara, H., Brownlee, M., Manogue, K. R., Dinarello, C. A. & Pasagian, A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240, 1546-1548 (1988).
144. Kirstein, M. et al. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc. Natl Acad. Sci. USA 87, 9010-9014 (1990). (Pubitemid 120007639)
145. Chen, Y. et al. RAGE ligation affects T cell activation and controls T cell differentiation. J. Immunol. 181, 4272-4278 (2008).
146. Imani, F. et al. Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling. J. Exp. Med. 178, 2165-2172 (1993). (Pubitemid 23344874)
147. Kinkhabwala, M. et al. A novel addition to the T cell repertory. Cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells. J. Exp. Med. 171, 941-946 (1990). (Pubitemid 20088994)
148. Feuerer, M., Shen, Y., Littman, D. R., Benoist, C. & Mathis, D. How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity 31, 654-664 (2009).
149. Chen, A. et al. Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obes. Res. 13, 1311-1320 (2005).
150. Bordone, L. et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol. 4, e31 (2006).
151. Böni-Schnetzler, M. et al. Increased interleukin (IL)-1β messenger ribonucleic acid expression in beta -cells of individuals with type 2
152. Dinarello, C. A., Donath, M. Y. & Mandrup-Poulsen, T. Role of IL-1β in type 2 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 17, 314-321 (2010).
153. Evans, J. L., Goldfine, I. D., Maddux, B. A. & Grodsky, G. M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev. 23, 599-622 (2002). (Pubitemid 35191625)
154. Vlassara, H. et al. Identifying advanced glycation end products as a major source of oxidants in aging: implications for the management and/or prevention of reduced renal function in elderly persons. Semin. Nephrol. 29, 594-603 (2009).
155. Ogden, C. L. et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295, 1549-1555 (2006).
156. Dabelea, D. The accelerating epidemic of childhood diabetes. Lancet 373, 1999-2000 (2009).
157. Dabelea, D. et al. Association of intrauterine exposure to maternal diabetes and obesity with type 2 diabetes in youth: the SEARCH Case-Control Study. Diabetes Care 31, 1422-1426 (2008).
158. Alexander, B. T. & Ojeda, N. B. Prenatal inflammation and the early origins of hypertension. Clin. Exp. Pharmacol. Physiol. 35, 1403-1404 (2008).
159. Ojeda, N. B., Grigore, D. & Alexander, B. T. Developmental programming of hypertension: insight from animal models of nutritional manipulation. Hypertension 52, 44-50 (2008).
160. Nivoit, P. et al. Established diet-induced obesity in female rats leads to offspring hyperphagia, adiposity and insulin resistance. Diabetologia 52, 1133-1142 (2009).
161. Ling, C. et al. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia 51, 615-622 (2008).
162. Ling, C. & Groop, L. Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 58, 2718-2725 (2009).
163. Mericq, V. et al. Maternally transmitted and food-derived glycotoxins: a factor preconditioning the young to diabetes? Diabetes Care 33, 2232-2237 (2010).
164. Dittrich, R. et al. Concentrations of Nepsilon-carboxymethyllysine in human breast milk, infant formulas, and urine of infants. J. Agric. Food Chem. 54, 6924-6928 (2006). (Pubitemid 44426978)
165. Birlouez-Aragon, I. et al. Assessment of protein glycation markers in infant formulas. Food Chemistry 87, 253-259 (2004). (Pubitemid 38584610)
166. Wilkin, T. J. Diabetes: 1 and 2, or one and the same? Progress with the accelerator hypothesis. Pediatr. Diabetes 9, 23-32 (2008). (Pubitemid 351784992)
167. Gale, E. A. The rise of childhood type 1 diabetes in the 20th century. Diabetes 51, 3353-3361 (2002). (Pubitemid 35403436)
168. Couper, J. J. et al. Weight gain in early life predicts risk of islet autoimmunity in children with a first-degree relative with type 1 diabetes. Diabetes Care 32, 94-99 (2009).
169. Semba, R. D., Bandinelli, S., Sun, K., Guralnik, J. M. & Ferrucci, L. Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults. J. Am. Geriatr. Soc. 57, 1874-1880 (2009).
170. Semba, R. D., Najjar, S. S., Sun, K., Lakatta, E. G. & Ferrucci, L. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am. J. Hypertens. 22, 74-79 (2009).
171. Semba, R. D., Fink, J. C., Sun, K., Windham, B. G. & Ferrucci, L. Serum carboxymethyl-lysine, a dominant advanced glycation end product, is associated with chronic kidney disease: the Baltimore longitudinal study of aging. J. Ren. Nutr. 20, 74-81 (2010).
172. Uribarri, J. et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J. Am. Soc. Nephrol. 14, 728-731 (2003). (Pubitemid 36246017)
173. Uribarri, J. et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J. Am. Diet Assoc. 110, 911-916 (2009).
174. Akkarachaneeyakorn, S. et al. Optimization of combined microwave-hot air roasting of malt based on energy consumption and neo-formed contaminants content. J. Food Sci. 75, E201-E207 (2010).
175. Miura, J. et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with type 1 diabetes. J. Diabetes Complications 17, 16-21 (2003). (Pubitemid 36042787)
176. Gul, A., Rahman, M. A., Salim, A. & Simjee, S. U. Advanced glycation end products in senile diabetic and nondiabetic patients with cataract. J. Diabetes Complications 23, 343-348 (2009).
177. Goh, S. Y. & Cooper, M. E. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 93, 1143-1152 (2008). (Pubitemid 351519698)